Corporate Governance

Ms. Tetrault, who has been a Board Member since June 2015, served as Lead Independent Director from 2020 to 2021 and was appointed Non-Executive Chair in October 2021. Previously, Ms. Tetrault served in a variety of executive roles at AstraZeneca PLC from 1993 to 2014 including Executive Vice President of Human Resources and Corporate Affairs from 2007 to 2014. Ms. Tetrault also serves as a Non-Executive Director of Rhythm Pharmaceuticals. Ms. Tetrault has an undergraduate degree from Princeton University and a J.D. from the University of Virginia Law School.

Tony became CEO of NeoGenomics in April 2025. Prior to becoming CEO, he was a Board member for two years, serving as Chair of the Compensation committee and a member of the Audit and Technology committees. Tony has significant experience as a brand and marketing executive, with a focus on managing the interface between commercial and research and development aspects of an organization. Prior to serving as Chief Executive Officer of Innocoll Biotherapeutics, Tony was Executive Vice President, Commercial Operations of AstraZeneca (AZ), where he held global P&L responsibility for all of AZ’s brands and markets. Under Tony’s leadership, AZ commercialized 10 brands, each in excess of $1 billion in sales. Tony was responsible for MedImmune, AZ’s global biologics business. He also chaired the Commercial Investment Board, which identified and approved critical investments company-wide, including investments in plants, markets, and technology. Earlier in his career at AZ, Tony held various positions, including CEO of North America and VP of Sales, where he helped lead the integrations of Astra US, Astra Merck, and Zeneca. Prior to joining AZ, Tony spent 14 years with Berlex Laboratories in a variety of positions.

Dr. Hannah has served as a director since June 2015. Dr. Hannah has over 25 years' experience in the development of investigational cancer chemotherapies. Since 2000, she has served as a consultant to the pharmaceutical industry, working with over 20 companies with a focus on molecularly targeted therapy. Prior to this, she worked as Senior Medical Director at SUGEN on various compounds, including Sutent approved in kidney cancer, and Quintiles, a global Contract Research Organization. Dr. Hannah specializes in clinical development strategy, and has filed over 30 Investigational New Drug applications for new molecular entities and 7 New Drug Applications. She participates in Data Monitoring Committees, Scientific Advisory Boards and Independent Review Committees for clinical trials. She has a bachelor's degree in biochemistry and immunology from Harvard University and her medical degree from the University of Saint Andrews. She is a member of ASCO, AACR, ASH, ESMO and a Fellow with the Royal Society of Medicine.

Mr. Kelly is a former senior executive of Amgen, Inc. and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by Mr. Kelly in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc., most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Tanox and Monsanto Life Sciences. Mr. Kelly serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations.

With 40 years of executive leadership in medical device and health care services, David Perez serves as an independent board member and advisor to several corporations and non-profit organizations. His expertise encompasses growing and scaling highly regulated global businesses organically through R&D and innovation and inorganically through M&A, leading within a variety of foreign, public and private equity ownership structures, strategic planning, culture and talent development, succession planning, enterprise risk management, operations, compliance, and corporate governance.

Mr. Kanovsky recently retired as Deputy General Counsel of GE HealthCare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics. In addition to pharmaceutical research experience and private practice legal experience, Mr. Kanovsky has over 25 years of legal experience in the global life sciences and biotechnology industry. Mr. Kanovsky earned his bachelor's degree in Chemistry and Biophysics from the University of Pennsylvania. He subsequently graduated from Temple University's School of Pharmacy with a master's degree in Pharmacology and Temple University's School of Law with a juris doctorate degree. Mr. Kanovsky also holds a master's degree in business administration from Saint Joseph University's Haub School of Business. He has been an Adjunct Professor for Saint Joseph’s MBA programs. He is also a co-editor of and contributing author to the Food and Drug Law Institute’s “A Practical Guide to FDA’s Food and Drug Law and Regulation” (Seventh Edition, 2020).

Elizabeth Floegel has a track record for successfully leading technology and organizational transformation in highly matrixed environments. As Chief Information & Digital Officer of Numotion, Elizabeth is managing a significant digital and cybersecurity transformation with the strategic use of data and technology to drive value creation by creating efficient and compliant operations. Before joining Numotion, Ms. Floegel was the Global Vice President of Business Technology at Allergan (now part of Abbvie). In her time at Allergan, she led the technology portfolio across global commercial, retail, digital products and marketing. Ms. Floegel's earlier roles include Head of Commercial and Digital Technology for Regeneron Pharmaceuticals and Global Vice President of Commercial Technology for Baxter Healthcare.

Neil Gunn is a veteran Diagnostics senior executive with expertise in company organization to maximize efficiencies with a focus on value generators to drive growth. Most recently, Neil was the Chief Executive Officer of IDbyDNA, which was acquired by Illumina in 2022. Prior to that, Dr. Gunn was President of Roche Sequencing Solutions (RSS), where he grew the organization from early initial concepts to over 900 employees across three continents while integrating nine acquisitions into one with a common vision and strategy. Before RSS, Dr. Gunn was Head of Global Business for Roche Molecular Diagnostics (RMD) and was responsible of the development and execution of strategic plan that launched over 140 major assay, instrument, and software launches over six years. Neil's earlier roles include Vice President Commercial Operations for CaridianBCT and Vice President of Commercial Operations - Americas for Novartis Diagnostics.

Felicia Williams retired from Macy’s, Inc. in November 2023 after having served for three years as the Macy’s Fellow for CEO Action for Racial Equity; a fellowship of seasoned executives and highly skilled subject matter experts that provided 2,000+ CEOs with an opportunity to advance racial equity through public policy. Prior to being appointed to the fellowship, Williams served as the Interim CFO and Risk Officer for Macy’s, Inc. from June 2000 to November 2000. Williams was named the Chief Accounting Officer, Controller and Enterprise Risk Officer on June 1, 2016. She was formerly Vice President responsible for enterprise risk and internal audit.

Williams began serving as Vice President of risk management and financial services, which included the risk management, accounts payable, expense payable, payroll, and travel functions in February 2011. Williams was also Vice President, treasury, investor relations, and risk management in September 2009.

Williams joined Macy’s as Vice President, internal audit in 2004, after having served as Director of internal audit for Coca-Cola Hellenic Bottling Company in Athens, Greece for two years. She began her career with the Coca-Cola system in 1994, as a commercial paper trader and money market analyst for The Coca-Cola Company in Atlanta, GA. She held a variety of positions in the treasury area before being named executive assistant to the chief financial officer in 1997. In 1999, she joined the controller’s group and held positions of increasing responsibility in the finance and treasury services areas.

Prior to joining Coca-Cola, Williams worked for Bristol-Myers Squibb in New York City and Arthur Andersen & Company in Washington, D.C.

Williams currently serves as a member of the board and audit committee chair for Anywhere Real Estate (formerly Realogy Holdings Corp) and Paycom, LLC. Prior to taking the company private, Williams was also the former audit committee chair and board member for Meridian Bioscience.

Williams also has a deep and diverse commitment to community service; her background includes former member of the board of the Manhattan Theater Company in New York City, as the board chair of Ronald McDonald House of Greater Cincinnati, as the chair of the audit, finance and investment committees for Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio, as a member of the finance and investment committee of ArtsWave, and as a member of the board and finance committee of The Children’s Theater of Cincinnati. She has received numerous awards, including the 2006 YWCA Career Women of Achievement.

Williams, a native of Chicago, is a summa cum laude graduate of Florida A&M University and a certified public accountant.